Review article Open access
Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)
A series of phase II and randomised phase III trials in Asia and Europe have confirmed recently that advanced stage non-small-cell lung carcinoma patients with adenocarcinoma subtypes harbouring specific mutations when subjected to targeted therapy experience equivalent survival outcomes as those treated with chemother …